MedPath
FDA Approval

Rivastigmine Transdermal System

October 31, 2020

HUMAN PRESCRIPTION DRUG LABEL

Rivastigmine(4.6 mg in 1 1)

Products (3)

Rivastigmine Transdermal System

47781-304

ANDA204403

ANDA (C73584)

TRANSDERMAL

June 11, 2012

POLYISOBUTYLENE (400000 MW)Inactive
Code: X9N69O5R5XClass: IACT
POLYISOBUTYLENE (1100000 MW)Inactive
Code: FLT10CH37XClass: IACT
Code: PKI06M3IW0Class: ACTIBQuantity: 4.6 mg in 1 1
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
LIGHT MINERAL OILInactive
Code: N6K5787QVPClass: IACT

Rivastigmine Transdermal System

47781-305

ANDA204403

ANDA (C73584)

TRANSDERMAL

June 11, 2012

Code: PKI06M3IW0Class: ACTIBQuantity: 9.5 mg in 1 1
POLYISOBUTYLENE (400000 MW)Inactive
Code: X9N69O5R5XClass: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
LIGHT MINERAL OILInactive
Code: N6K5787QVPClass: IACT
POLYISOBUTYLENE (1100000 MW)Inactive
Code: FLT10CH37XClass: IACT

Rivastigmine Transdermal System

47781-405

ANDA204403

ANDA (C73584)

TRANSDERMAL

June 11, 2012

SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
POLYISOBUTYLENE (400000 MW)Inactive
Code: X9N69O5R5XClass: IACT
Code: PKI06M3IW0Class: ACTIBQuantity: 13.3 mg in 1 1
LIGHT MINERAL OILInactive
Code: N6K5787QVPClass: IACT
POLYISOBUTYLENE (1100000 MW)Inactive
Code: FLT10CH37XClass: IACT
© Copyright 2025. All Rights Reserved by MedPath